Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: Exploratory analyses of the MRI sub-group of the Alphase study

Journal of Nutrition, Health and Aging

Volumn 13, Issue 6, 2009, Pages 550-557

  Gauthier, S ^a   Aisen, P S ^b   Ferris, S H ^c,d   Saumier, Daniel ^e   Duong, A ^e   Haine, D ^f   Garceau, D ^g   Suhy, J ^h   Oh, J ^h   Lau, W ^h   Sampalis, J ⁱ  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^e BELLUS Health Inc   (Canada)

^f JSS Medical Research   (Canada)

^g OVOS Natural Health Inc   (Canada)

^h SYNARC INC   (United States)

ⁱ ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Alzheimer's disease; Amyloid; Hippocampus; Homotaurine; MRI; Tramiprosate

Indexed keywords

DONEPEZIL; GALANTAMINE; HOMOTAURINE; MEMANTINE; PLACEBO; RIVASTIGMINE; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; DRUG DERIVATIVE; NEUROPROTECTIVE AGENT; TAURINE;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN SIZE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG SAFETY; FEMALE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT DURATION; TREATMENT RESPONSE; DRUG ANTAGONISM; HOSPITALIZATION; MIDDLE AGED; PATHOLOGY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; SEVERITY OF ILLNESS INDEX; TAURINE;

EID: 70349637413     PISSN: 12797707     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12603-009-0106-x     Document Type: Article

References (32)

1. Canaveri L, Abramov A, & Duchen MR Toxicity of amyloid B peptide: Tales of calcium, mitochondria, and oxidative stress. Neurochem Res 2004; 29: 637-650.
2. Goshe KM, Mortimer JA, Smith CD, et al. Hippocampal volume as an index of Azheimer neuropathology: findings from the Nun study. Neurology 2002; 58: 1476-1482
3. Haroutunian V, Perl DP, Purohit DP, et al. Regional distribution of neuritic plaques in the non-demented elderly and subjects with very mild Alzheimer disease. Arch. Neurol 1998; 55: 1185-1191.
4. Goshe KM, Mortimer JA, Smith CD, et al. Hippocampal volume as an index of Azheimer neuropathology: findings from the Nun study. Neurology 2002; 58: 1476-1482
5. Convit A, de Leon MJ, Golomb J, et al. Hippocampal atrophy in early Alzheimer's disease: anatomic specificity and validation. Psychiatric Quarterly 1993; 64: 371-387.
6. Csernansky JG, Wang L, Joshi S, et al. Early DAT is distinguished from aging by high-dimensional mapping of the hippocampus. Neurology 2000; 55: 1636-1643.
7. Dickerson BC, Goncharova I, Sullivan MP, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiology of Aging 2001; 22: 747-754.
8. Du AT, Schuff N, Amend D, et al. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry 2001; 71: 441-447.
9. Du AT, Schuff N, Kramer JH, et al. Higher Atrophy Rate of Entorhinal Cortex than Hippocampus in AD. Neurology 2004; 62: 422-427.
10. Krasuski JS, Alexander GE, Horwitz B, et al. Relation of medial temporal lobe volumes to age and memory function in non-demented adults with Down's syndrome: implications for the prodromal phase of Alzheimer's disease. American Journal of Psychiatry 2002; 159: 74-81.
11. Mega MS, Small GW, Xu ML, et al. Hippocampal atrophy in persons with age-associated memory impairment: volumetry within a common space. Psychosomatic Medicine 2002; 64; 487-492.
12. Mu Q, Xie J, Wen Z, et al. A quantitative MR study of the hippocampal formation, the amygdale, and the temporal horn of the lateral ventricle in healthy subjects 40 to 90 years of age. American Journal of Neuroradiology 1999; 20: 207-211.
13. Xu Y, Jack CRJ, O'Brien PC, et al. Usefulness of MRI measures of entrorhinal versus hippocampus in AD. Neurology 2000; 14: 531-545.
14. Petersen RC, Jack CR Jr, Xu YC, et al. Memory and MRI-based hippocampal volumes in aging and AD. Neurology 2000; 54: 581-587.
15. Persson J, Nyberg L, Lind J, et al. Structure-function correlates of cognitive decline in aging. Cereb Cortex 2006; 16: 907-915.
16. Saykin AJ, Wishart HA, Rabin LA, et al. Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology 2006; 67: 834-842.
17. Citron, M. Strategies for disease modification in Alzheimer's disease. Nature Reviews 2004; 5: 677-685.
18. Gervais F, Paquette J, Morissette C, et al. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 2007; 28:537-547.
19. Krzywkowski P, Sebastiani G, Williams S, et al. Tramiprosate Prevents Amyloid Beta-induced Inhibition of Long-term Potentiation in Rat Hippocampal Slices. 8th International Conference AD/PD, Salzburg, Austria, March 14-18. 2007.
20. Azzi M, Morissette C, Fallon L, et al. Involvement of both GABA-dependent and - independent pathways in tramiprosate neuroprotective effects against amyloid-beta toxicity. 8th International Conference AD/PD, Salzburg, Austria, March 14-18. 2007.
21. Aisen PS, Saumier D, Briand R, et al. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 2006; 67:1757-63.
22. Aisen PS, Gauthier S, Ferris SH, et al. Tramiprosate in Mild to Moderate Alzheimer's Disease: a Randomized, Double-blind, Placebo-controlled, Multi-centre study (the Alphase study). Submitted.
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition, Text Revision. 2000. Washington, DC, American Psychiatric Association, 154-158.
24. McKhann G, Drachman D, Folskein M, et al. Clinical Diagnosis of Alzheimer's Disease: Report of the NINCDS-ADRDA Word Group under the Auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
25. Folstein MF, Folstein SE and McHugh PR. "Mini-Mental State" A Practical Method for Grading the Cognitive State of Patients for the Clinician. J Psychiat Res 1975; 12: 189-198.
26. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: A preliminary report. Journal of Psychiatric Research 1983; 17: 37-49.
27. Singer JD. Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. JEBS 1998; 24: 323-55.
28. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. Springer, New York, 2000. p.568
29. Littell RC, Milliken GA, Stroup WW, et al. SAS for mixed models. SAS Institute, Cary NC, 2006, pp.813
30. West BT, Welch KB, Galecki AT. Linear mixed models. A practical guide using statistical software. Chapman & Hall/CRC, Boca Raton FL, 2007. pp.353
31. Edwards D, Berry JJ. The efficiency of simulation-based multiple comparisons. Biometrics 2007; 43: 913-28.
32. Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. American Journal of Psychiatry 1994; 151: 390-6.